GGrantIndex
← Leaderboards

Chun R. Chao

Kaiser Foundation Research Institute

$8,592,282
Attributed
$11,006,821
Total exposure
6
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.4M · FY200825
$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$11,656,813 · 7

By mechanism

R01$10,612,087 · 5
U54$649,992 · 1
R21$394,734 · 1

Top collaborators

Most similar at Kaiser Foundation Research Institute

Same institution · by research overlap

Others in their field

Top investigators on “California

Research focus

CaliforniaMalignant NeoplasmsInsightRecommendationUnited StatesEnvironmentDiagnosisCohortVariantCharacteristicsCaringResourcesMolecularSubgroupCancer DiagnosisAffectElectronic Health RecordBiometryArchivesResponseSpecimenClinicDesignBase

Grant awards (22)

Effectiveness of the HPV Vaccine in Immunocompromised Populations$827,605
R01 · FY2025 · AI
Effectiveness and Mechanisms of Multilevel Implementation Strategies to Improve Cancer Prevention Behaviors: A Cluster Randomized Trial$612,449
R01 · FY2025 · CA · contact PI
Effectiveness of the HPV Vaccine in Immunocompromised Populations$826,914
R01 · FY2024 · AI
Effectiveness and Mechanisms of Multilevel Implementation Strategies to Improve Provider Recommendation and Advance HPV Vaccination: a Cluster Randomized Trial$593,242
R01 · FY2024 · CA · contact PI
Effectiveness and Mechanisms of Multilevel Implementation Strategies to Improve Provider Recommendation and Advance HPV Vaccination: a Cluster Randomized Trial$627,341
R01 · FY2023 · CA · contact PI
A Case-Control Study to Evaluate Broad-Spectrum Antibiotic use and High Birth Weight as Potential Risk Factors for Early-Onset Colorectal Cancer$360,475
R01 · FY2023 · CA · contact PI
Effectiveness and Mechanisms of Multilevel Implementation Strategies to Improve Provider Recommendation and Advance HPV Vaccination: a Cluster Randomized Trial$649,552
R01 · FY2022 · CA · contact PI
A Case-Control Study to Evaluate Broad-Spectrum Antibiotic use and High Birth Weight as Potential Risk Factors for Early-Onset Colorectal Cancer$362,122
R01 · FY2022 · CA · contact PI
Effectiveness and Mechanisms of Multilevel Implementation Strategies to Improve Provider Recommendation and Advance HPV Vaccination: a Cluster Randomized Trial$691,976
R01 · FY2021 · CA · contact PI
A Case-Control Study to Evaluate Broad-Spectrum Antibiotic use and High Birth Weight as Potential Risk Factors for Early-Onset Colorectal Cancer$379,857
R01 · FY2021 · CA · contact PI
Identification of DNA methylation markers for risk of metastasis in localized pro$646,064
R01 · FY2019 · CA · contact PI
Identification of DNA methylation markers for risk of metastasis in localized pro$594,195
R01 · FY2018 · CA · contact PI
Identification of DNA methylation markers for risk of metastasis in localized pro$566,816
R01 · FY2017 · CA · contact PI
Follow-up care and preventive service use among survivors of adolescent and young adult cancer.$177,068
R21 · FY2017 · CA · contact PI
Identification of DNA methylation markers for risk of metastasis in localized pro$571,325
R01 · FY2016 · CA · contact PI
Follow-up care and preventive service use among survivors of adolescent and young adult cancer.$217,666
R21 · FY2016 · CA · contact PI
Identification of DNA methylation markers for risk of metastasis in localized pro$639,726
R01 · FY2015 · CA · contact PI
Optimizing Colonscopy & Fecal Immunochemical Tests for Community-Based Screening$649,992
U54 · FY2014 · CA
Prognostic Markers for HIV-Postive Diffuse Large B-Cell Lymphoma$301,385
R01 · FY2011 · CA · contact PI
Prognostic Markers for HIV-Postive Diffuse Large B-Cell Lymphoma$357,589
R01 · FY2010 · CA · contact PI
Prognostic Markers for HIV-Postive Diffuse Large B-Cell Lymphoma$503,454
R01 · FY2009 · CA · contact PI
Prognostic Markers for HIV-Postive Diffuse Large B-Cell Lymphoma$500,000
R01 · FY2008 · CA · contact PI